175203-34-6 Usage
Molecular Structure
2-(2,3-Dihydro-1,4-benzodioxin-2-yl)-1,3-thiazole-4-carboxylic acid consists of a benzodioxin ring fused to a thiazole ring, with a carboxylic acid group attached to the thiazole ring.
Purity
The compound is available in a concentration of 90% or higher, indicating a high level of purity.
Potential Applications
This chemical has potential applications in pharmaceutical research, as both benzodioxin and thiazole derivatives have been studied for their biological activities.
Biological Activities
Benzodioxin and thiazole derivatives have been researched for their anticancer, antimicrobial, and anti-inflammatory properties.
Further Research
More studies are needed to fully understand the potential uses and properties of 2-(2,3-Dihydro-1,4-benzodioxin-2-yl)-1,3-thiazole-4-carboxylic acid, 90%+.
Check Digit Verification of cas no
The CAS Registry Mumber 175203-34-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,5,2,0 and 3 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 175203-34:
(8*1)+(7*7)+(6*5)+(5*2)+(4*0)+(3*3)+(2*3)+(1*4)=116
116 % 10 = 6
So 175203-34-6 is a valid CAS Registry Number.
175203-34-6Relevant articles and documents
Discovery of 2-aminothiazole-4-carboxamides, a novel class of muscarinic M3 selective antagonists, through solution-phase parallel synthesis
Sagara, Yufu,Mitsuya, Morihiro,Uchiyama, Minaho,Ogino, Yoshio,Kjmura, Toshifumi,Ohtake, Norikazu,Mase, Toshiaki
, p. 437 - 440 (2005)
Synthesis and structure-activity relationship of a new class of muscarinic M3 selective antagonists were described. In the course of searching for a muscarinic M3 antagonist with a structure distinct from those of the 2-(4,4-difluorocyclopentyl)-2-phenylacetamide derivatives, we identified a thiazole-4-carboxamide derivative (1) as a lead compound in our in-house chemical collection. Since this compound (1) showed relatively low binding affinity (K1 = 140 nM) for M3 receptors in the human binding assays, we tried to improve its potency and selectivity for M 3 over M1 and M2 receptors by derivatization of 1 through a combinatorial approach. A solution-phase parallel synthesis effectively contributed to the optimization of each segment of 1. Thus, we have identified a cyclooctenylmethyl derivative (3e) and a cyclononenylmethyl derivative (3f) as representative M3 selective antagonists in this class.
Xi:Irritant;
